A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Affiliation
The Fifth Medical Center, People�s Liberation Army General Hospital, Beijing, ChinaIssue Date
2019
Metadata
Show full item recordCitation
Xu J-M, Kato K, Hubner RA, Raymond E, Xu Y, Liu S, et al. A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC). J Clin Oncol. 2019;37(15_suppl):TPS2656-TPS.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.TPS2656Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS2656Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.TPS2656